Divi's Laboratories (NSE:DIVISLAB) Cash-to-Debt : N/A (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Divi's Laboratories's cash to debt ratio for the quarter that ended in Dec. 2023 was N/A.

The historical rank and industry rank for Divi's Laboratories's Cash-to-Debt or its related term are showing as below:

NSE:DIVISLAB' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.37 Med: 46.21 Max: 1268.27
Current: 723.2

During the past 13 years, Divi's Laboratories's highest Cash to Debt Ratio was 1268.27. The lowest was 13.37. And the median was 46.21.

NSE:DIVISLAB's Cash-to-Debt is ranked better than
92.94% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs NSE:DIVISLAB: 723.20

Divi's Laboratories Cash-to-Debt Historical Data

The historical data trend for Divi's Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Divi's Laboratories Cash-to-Debt Chart

Divi's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

13.37

26.40

431.67

743.03

1,268.27

Divi's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															N/A	1,268.27	N/A	723.20	N/A

Competitive Comparison of Divi's Laboratories's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Divi's Laboratories's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Cash-to-Debt falls into.

Divi's Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Divi's Laboratories's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	41345.5	/	(4.9	+	27.7)
	=	1,268.27

Divi's Laboratories's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Divi's Laboratories (NSE:DIVISLAB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Divi's Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Divi's Laboratories (NSE:DIVISLAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » Cash-to-Debt

Traded in Other Exchanges

532488:India

Address

Divi Towers, 1-72/23(P)/DIVIS/303, Babukhan Lane, Cyber Hills, Gachibowli, Hyderabad, TG, IND, 500032

Website

https://www.divislabs.com

Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Divi's Laboratories (NSE:DIVISLAB) Headlines

No Headlines